Last updated on June 2019

Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy


Brief description of study

To demonstrate the effectiveness of riociguat as replacement of phosphodiesterase-5 inhibitors (PDE-5i) therapy in pulmonary arterial hypertension (PAH) patients

Detailed Study Description

Data from a previous single arm study (RESPITE) indicate that transition from PDE5i to riociguat may be feasible, safe and beneficial in patients not adequately responding to PDE5i.

REPLACE is a randomized controlled study to confirm the potential clinical benefit of transition from PDE5i to riociguat. Satisfactory clinical response in patients who are on a stable dose of phosphodiesterase-5inhibitors (PDE-5i) with or without endothelin receptor antagonist (ERA), but not at treatment goal will be compared between one group of patients randomized to maintain current treatment and another group where the PDE5i is replaced by riociguat.

Clinical Study Identifier: NCT02891850

Find a site near you

Start Over

Bayer Clinical Trials Contact

Le Kremlin-Bicêtre, France
8.09miles
  Connect »

Bayer Clinical Trials Contact

Le Kremlin-Bicêtre, France
8.09miles
  Connect »

Bayer Clinical Trials Contact

Le Kremlin-Bicêtre, France
8.09miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.